[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behavioral-activation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behavioral-activation":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100574730",false,"NCT06763081","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)","PGx-SImBA","Inclusion criteria: Participants will be eligible for participation if all of the following are true.\n\n* Resident of Manitoba\n* Age, 6 - 24 years\n* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)\n* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \\[Celexa\\], Escitalopram \\[Cipralex\\], Fluoxetine \\[Prozac\\], Fluvoxamine \\[Luvox\\], Sertraline \\[Zoloft\\], Paroxetine \\[Paxil\u002FPlaxil CR\\]) therapy\n* \\[Cases Only\\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug\n* \\[Controls Only\\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks\n\nExclusion criteria: Participants will be excluded from participation if any of the following are true.\n\n* Inability of parent\u002Flegal guardian\u002Fmature minors to give informed consent\n* Inability of the child (6 - 13 years) to give informed assent\n* Unwillingness of the child to provide a saliva sample for genetic analysis\n* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder\n* History of liver or bone marrow (hematopoietic cell) transplant.","ALL","6 Years","24 Years",{"count":20,"type":21},160,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[25,26,27,28,29,30],"Behavioral Activation","Major Depressive Disorder","Anxiety Disorders","Antidepressant Drug Adverse Reaction","Obsessive Compulsive Disorder (OCD)","Major Depression",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"SSRI","Depression","OCD","Anxiety","Antidepressants","Children","Adolescents","Mood Disorders","Drug-induced Adverse Events","Youth","Mental Illness","Mental disorders","Drug-Related Side Effects and Adverse Reactions","Selective Serotonin Reuptake Inhibitor","Disinhibition","RECRUITING","2025-09-01",{"date":50,"type":51},"2025-09-08","ACTUAL",{"date":53,"type":51},"2025-03-01",{"date":55,"type":21},"2030-12-31",{"name":57,"class":58},"University of Manitoba","OTHER",2,""]